ImmunityBio (IBRX)
NASDAQ:IBRX
Holding IBRX?
Track your performance easily

ImmunityBio (IBRX) Income Statement

1,149 Followers

ImmunityBio Income Statement

Last quarter (Q ), ImmunityBio's total revenue was $1.05M, an increase of 2453.66% from the same quarter last year. In Q, ImmunityBio's net income was $-134.56M. See ImmunityBio’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 1.31M$ 622.00K$ 240.00K$ 934.00K$ 605.00K
Cost of Revenue
-----
Gross Profit
$ 1.31M$ 622.00K$ 240.00K$ 934.00K$ 605.00K
Operating Expense
$ 360.48M$ 361.99M$ 351.54M$ 331.21M$ 221.49M
Operating Income
$ -360.05M$ -362.25M$ -351.30M$ -330.28M$ -220.88M
Net Non Operating Interest Income Expense
$ 132.10M$ 128.34M$ -63.52M$ -14.85M$ -9.07M
Other Income Expense
$ -92.53M$ -94.19M$ 3.15M$ 4.71M$ 6.78M
Pretax Income
$ -597.81M$ -583.89M$ -417.29M$ -349.84M$ -226.03M
Tax Provision
$ -40.00K$ -40.00K$ 34.00K$ 9.00K$ -1.85M
Earnings From Equity Interest Net Of Tax
$ -1.25M$ -7.55M$ -12.11M$ -803.00K-
Net Income Common Stockholders
$ -597.65M$ -583.20M$ -416.57M$ -346.79M$ -221.85M
Basic EPS
$ -0.96$ -1.15$ -1.04$ -0.89$ -0.89
Diluted EPS
$ -0.96$ -1.15$ -1.04$ -0.89$ -0.89
Basic Average Shares
$ 2.53B$ 508.64M$ 399.90M$ 389.23M$ 103.55M
Diluted Average Shares
$ 2.53B$ 508.64M$ 399.90M$ 389.23M$ 103.55M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 361.36M$ 361.99M$ 351.54M$ 331.21M$ 221.49M
Net Income From Continuing And Discontinued Operation
$ -597.65M$ -583.20M$ -416.57M$ -346.79M$ -221.85M
Normalized Income
$ -574.19M$ -583.05M---
Interest Expense
-----
EBIT
$ -394.88M$ -454.69M$ -353.77M$ -337.10M$ -216.96M
EBITDA
$ -362.66M$ -436.18M$ -335.51M$ -320.75M$ -204.22M
Currency in USD

ImmunityBio Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis